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Cases in primary care laboratory medicine
Paraprotein management
W Stuart A Smellie, Gavin P Spickett
This article explores best practice in the investigation and monitoring of paraprotein bands in blood
or urine. It looks at the pitfalls and provides a summary of guidance
We present two cases illustrating the use of
electrophoresis in the diagnosis and monitoring of
plasma cell dyscrasias. The presence of monoclonal
protein bands (paraproteins) in myeloma is well recog-
nised; other conditions in which paraproteins may be
seen are less well understood, as is the relatively
common monoclonal gammopathy of unknown
significance (MGUS) often previously referred to as
benign paraproteinaemia.
Case 1
A 58 year old woman was referred urgently to
hospital with a three month history of lethargy, weight
loss, dysphagia, and nausea. On the day she was seen
by her general practitioner she was weak and
hypotensive (90/58 mm Hg). Examination showed an
underweight woman (body mass index 19) with a
blood pressure of 90/60 mm Hg, pulse 90 beats per
minute, muscle wasting, no oedema, and no focal neu-
rological signs.
Results of initial laboratory investigations were
sodium 128 mmol/l, potassium 5.2 mmol/l, urea 7.2
mmol/l, creatinine 105 mol/l, total protein 52 g/l,
albumin 27 g/l, aspartate transaminase 68 IU/l,
alanine transaminase 86 IU/l. Serum immunoglobu-
lins IgG, IgA, and IgM were within the reference range.
A short synacthen test produced blood cortisol
concentrations of 254 mmol/l at 0 minutes and
316 mmol/l at 30 minutes. She was given replacement
steroids and began to improve.
Investigation of her low serum albumin showed
proteinuria (total protein excretion 8.2 g/24 hours).
Serum electrophoresis showed no visible paraprotein
band, and a subsequent immunofixation was negative.
Urine electrophoresis showed a dense albumin band
and one additional band, typed by immunofixation as
kappa light chains (600 mg/l).
She was referred for nephrology assessment.
Serum amyloid component P (SAP) scintigraphy
showed heavy amyloid load in spleen and liver. In view
of these findings a renal biopsy was not performed,
and she was diagnosed as having primary amyloidosis
(AL amyloidosis). She was treated with melphalan and
dexamethasone.
Case 2
A 72 year old woman was referred to her local haema-
tology outpatient clinic for investigation of a normo-
cytic anaemia (haemoglobin 98 g/l) with normal blood
film, identified from a full blood count requested when
she attended her general practitioner with a recent
chest infection.
When seen, she was clinically anaemic, appeared
otherwise in good health, and reported no specific
symptoms. Two episodes of upper productive respira-
tory tract infection in the previous three months had
both responded to antibiotics.
Laboratory investigations showed an anaemia of
101 g/l, neutrophil count of 1.9×109/l and platelet
count of 110×109/l, plasma viscosity of 2.25, and
serum calcium (corrected) 2.83 mmol/l. Renal
function was unremarkable for age (serum urea 6.8
mmol/l, creatinine 98 mol/l), and urine was negative
on dipstick testing.
Serum total protein was 78 g/l, albumin was 38 g/l,
serum IgG was 36 g/l, and both IgA and IgM were
suppressed ( < 0.2 g/l). Serum protein electrophoresis
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showed a paraprotein band, typed by immunofixation
as IgG kappa and measured by densitometry to be
33 g/l. Urine electrophoresis showed no monoclonal
band.
Magnetic resonance imaging showed diffuse bony
lesions consistent with myeloma and the patient’s bone
marrow biopsy contained 34% plasma cells.
Her laboratory records showed that a protein elec-
trophoresis had been done four years earlier. It
contained a paraprotein band of 4 g/l, typed as IgG
kappa at the time of an unrelated hospital admission,
described in the discharge summary as probable
benign paraproteinaemia. Her blood count at that time
had been unremarkable and no follow-up samples had
been taken.
Discussion
These two cases illustrate the utility of serum and urine
protein electrophoresis in investigating and monitor-
ing diseases associated with paraproteins. Paraproteins
may be present in blood or urine, or both, and may be
absent in plasma cell dyscrasias. They are found in a
range of inflammatory and infectious diseases associ-
ated with polyclonal increases in  globulins. If they are
caused by infection, the bands will disappear after
effective treatment and do not indicate myeloma.1 2 If
they are not associated with a polyclonal increase in 
globulins, their presence in blood, particularly in small
quantities, may not be clinically important (mono-
clonal gammopathy of unknown significance, MGUS)
or may be associated with other diseases, including
amyloidosis, leukaemia, lymphoma, and infectious and
inflammatory diseases, or may occur as an incidental
finding.
MGUS
MGUS is found in about 1% of people over 50 years
old and in 3% of those over 70 years old.3 Paraprotein
concentrations over 20 g/l (IgG) or 10 g/l (IgA)4—
particularly when associated with Bence Jones proteins
(free light chains) in urine, anaemia, bone fracture or
bone pain, suppression of other immunoglobulin
classes, and renal impairment—are more likely to
reflect myeloma, although the diagnosis is based on an
increase in plasma cell content in bone marrow.
About 1.5% of cases of MGUS per year progress to
myeloma,5 and annual follow-up with electrophoresis
and densitometry is recommended to detect increasing
concentrations of paraprotein as an indicator of
the possible progression towards myeloma,1 in order
to guide the decision to investigate further and
begin treatment. Failure to monitor patients will
expose those few who do progress to risks of infection,
hypercalcaemia, and pathological fracture or renal
dysfunction.
Free light chains
Free light chains are nephrotoxic, and their presence
in urine is associated with renal disease both in
primary amyloidosis and myeloma. They are not
reliably detected by urine test strips.1 5 6 As they may be
present in patients with myeloma irrespective of
whether a serum paraprotein is present, urine
electrophoresis is an essential adjunct to serumelectro-
phoresis in investigations of possible plasma cell
dyscrasia.1 7 Immunofixation appearances similar to
those of free light chains (light chain ladders) may also
be seen in urine in inflammatory disease in elderly
people.8
Primary amyloidosis is a rare cause of nephrotic
syndrome. It is caused by a plasma cell dyscrasia
producing widespread organ deposition of amyloid
AL protein, which is formed as a result of monoclonal
light chain production.
In case 1, the light chains were identified as part
of the investigation of nephrosis. Amyloid was
suggested by the coexistence of Addison’s disease and
confirmed by serum amyloid P component (SAP)
scintigraphy.
What are the sources of evidence?
A review of best practice published in the Journal of
Clinical Pathology indicates the varying degrees of
evidence that back up these recommendations.9 The
What follow-up is required once a patient has
been found to have a paraprotein band?
• Initially 3-6 month electrophoresis for IgG, IgA, or
IgM bands of less than 15 g/l in patients without signs
or symptoms
• Annual electrophoresis thereafter for stable IgG,
IgA, or IgM bands of less than 15 g/l, where there are
no accompanying indicators for a plasma cell
dyscrasia
• Referral to a haematologist for IgA or IgG bands
> 15 g/l or IgG, IgA, or IgM bands < 15 g/l with
accompanying indicators for a plasma cell dyscrasia
and other Ig bands (IgE and IgD are rare)
• Immediate tests after initial identification of a
monoclonal band: full blood count, calcium, and renal
function
What are the uses of serum immunoglobulins
and electrophoresis?
Serum immunoglobulins should be measured and an
electrophoresis performed:
• As part of the primary screen for suspected plasma
cell dyscrasias (myeloma, lymphoma, chronic
lymphatic leukaemia, heavy chain disease, amyloid)
• As part of the diagnostic investigation of suspected
primary and secondary immunodeficiency—that is,
patients with recurrent documented infections
They are of secondary value in the investigation of:
• Liver disease
• Connective tissue disease
• Sarcoidosis
• Chronic infection
Useful websites
See first article in this series (8 July, p 83) for a list of
general websites
International Myeloma Organization (UK)
www.myeloma.org.uk—Information for patients and
professionals on myeloma and links to related topics
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guidance on use of serum electrophoresis and
monitoring of paraprotein bands is based on observa-
tional studies. The recommendation to include urine
electrophoresis when investigating possible plasma cell
dyscrasias is based on evidence of the limited perform-
ance and numbers of false negative diagnoses when
serum electrophoresis is used alone.
There is little evidence that monitoring for
established paraprotein bands in patients with
MGUS influences outcome. Although there is no evi-
dence that early treatment of low grade so called
smouldering myeloma delays the onset of active
disease, early treatment can reduce the development
of bone disease and the guidance to monitor patients
with MGUS would seem logical on these grounds. The
monitoring intervals recommended are based on
consensus guidance; no studies are available on the
influence of longer or shorter monitoring intervals on
outcome.
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St John’s wort, a panacea?
When my father’s GP surgery was ransacked in 1978
during the communal riots in Sri Lanka’s sadly
beautiful hill capital, Kandy, I went to pick up the
pieces and found this bottle with some of the tincture
still left. Almost as a reflex, I picked it up and brought
it with me when I came to England. Now it occupies a
prominent position in my personal library of 3000
rare and old medical volumes as a nostalgic (from the
Greek nostos, return home, + algos, pain) object. My
father’s surgery was first established in the late 1940s,
and I have no idea if he used the tincture as a treatment
or if it was a legacy from an earlier practice that he
bought.
The practice of hanging St John’s wort outside the
front door to protect from lightning was known for
several centuries. In medieval times people believed
that if you slept with a branch of it under your pillow
on St John’s Eve (the night before St John’s Tide), the
saint would appear in a dream, give his blessing, and
prevent you from dying during the following year.
The ancient Chinese used its leaves, seeds, and
bright yellow flowers for treating diseases. Another
species of the same genus—Hypericum androsaemum,
known as St Peter’s wort—was used as a mild purgative
and was recommended by ancient Roman herbalists
and physicians including Dioscorides and Galen.
Chappan Harris’s Medical Dictionary (1884) mentions
its use as an anodyne (pain killer). Matthew Robinson’s
Family Herbal (1889) gives additional uses for flow of
urine, vulnerary (venereal disease), falling sickness,
sciatica, and palsy.
In his physical dictionary published in 1708,
Stephen Blancard or Blanchard, a professor of history
at Middlesbrough who became a physician at Franeker
in the Netherlands, has an entry on St John’s wort,
describing it as, “an excellent diuretic and vulnerary
herb; a decoction of it cures Tertian agues and
Quartans; it stops spitting of blood, and expels gravel;
a tincture of the flower is excellent in mania, and the
flowers infused in Spirit of Wine kill worms; the
compound of this herb is much used; it is excellent for
bruises and aches, and for spitting of blood.”
Few herbs have been used in such a wide variety of
diseases. In addition to its role as an anthelmintic,
analgesic, anti-inflammatory, diuretic,
anti-haemorrhagic, antimalarial, antiepileptic, and
laxative, it has also been used in sexually transmitted
diseases, nerve palsies, and mania.
Its present revival in treating depression has restored
a little of its glory. When I smell the strong odour from
the remaining tincture I wonder if it holds other
virtues that we have not yet explored.
Anton Sebastian locum consultant, Surbiton
(sbstna@aol.com)
We welcome articles up to 600 words on topics such as
A memorable patient, A paper that changed my practice,My
most unfortunate mistake,or any other piece conveying
instruction, pathos, or humour. Please submit the
article on http://submit.bmj.com Permission is needed
from the patient or a relative if an identifiable patient is
referred to. We also welcome contributions for
“Endpieces,” consisting of quotations of up to 80 words
(but most are considerably shorter) from any source,
ancient or modern, which have appealed to the reader.
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